Logo 1 Logo 2

Repositioning Candidate Details

Candidate ID: R0155
Source ID: DB00558
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Zanamivir
Synonyms:
Molecular Formula: C12H20N4O7
SMILES: [H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO
Structure:
DrugBank Description: A guanido-neuraminic acid that is used to inhibit neuraminidase.
CAS Number: 139110-80-8
Molecular Weight: 332.3098
DrugBank Indication: For the prevention and treatment of influenza A and B.
DrugBank Pharmacology: Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.
DrugBank MoA: The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Targets: Neuraminidase; Neuraminidase; Sialidase-2
Inclusion Criteria: